Browsing Tag
KSI-101
2 posts
Kodiak Sciences (NASDAQ: KOD) bets Phase 3 momentum and 2027 cash runway can turn pipeline promise into a retina franchise
Kodiak Sciences is chasing a retina comeback with Phase 3 Zenkuda data, a longer cash runway, and major catalysts ahead. Read what happens next.
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!